PMID- 36742383
OWN - NLM
STAT- MEDLINE
DCOM- 20230207
LR  - 20240102
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - A real-world study of anlotinib combined with GS regimen as first-line treatment 
      for advanced pancreatic cancer.
PG  - 1110624
LID - 10.3389/fendo.2023.1110624 [doi]
LID - 1110624
AB  - BACKGROUND: Anlotinib may boost the efficacy of pancreatic cancer (PC) treatment 
      if timely added to the GS regimen (Gemcitabine, Tegafur-gimeracil-oteracil 
      potassium); however, no data has been published. This study evaluated the safety 
      and efficacy of anlotinib in combination with the GS regimen(hereafter referred 
      to as the A+GS regimen) in the first-line treatment of patients with unresectable 
      or metastatic PC. METHODS: Patients with unresectable or metastatic PC treated at 
      Yueyang Central Hospital and Yueyang People's Hospital between October 2018 and 
      June 2022 were enrolled in this retrospective real-world investigation. Treatment 
      efficacy was evaluated based on the overall survival (OS), progression-free 
      survival (PFS), disease control rate (DCR), and objective response rate (ORR), 
      while the treatment safety was assessed by the frequency of major adverse events 
      (AEs). RESULTS: Seventy-one patients were included in this study, 41 in the GS 
      group and 30 in the A+GS group. The A+GS group had a longer mPFS than the GS 
      group (12.0 months (95% CI, 6.0-18.0) and 6.0 months (95% CI, 3.0-8.1)), 
      respectively (P = 0.005). mOS was longer in the GS+A group) when compared with 
      the GS group (17.0 months (95%CI, 14.0-20.0) and 10.0 months (95% CI, 7.5-12.5)), 
      respectively (P = 0.018). The GS+A group had higher ORR (50.0% vs 26.8%, P = 
      0.045) and DCR (83.3% vs 58.5%, P = 0.026). Furthermore, there were no grade 4-5 
      AEs and no treatment-related deaths, and no discernible increase in AEs in the 
      GS+A group when compared with the GS group. CONCLUSION: The A+GS regimen therapy 
      holds great promise in managing treatment-naive advanced PC, except that future 
      prospective studies with larger sample sizes and multiple centers are required to 
      determine its efficacy and safety.
CI  - Copyright (c) 2023 Zhan, Hu, Da, Weng, Zhou, Wen, Liu, Fang, Shen, Zhou, Luo, Xu, 
      Zhan and Su.
FAU - Zhan, Gouling
AU  - Zhan G
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
AD  - Department of Oncology, Third Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Hu, Jianbing
AU  - Hu J
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Da, Shijian
AU  - Da S
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Weng, Jie
AU  - Weng J
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Zhou, Chuanyi
AU  - Zhou C
AD  - Department of Oncology, Yueyang People's Hospital, Yueyang, China.
FAU - Wen, Fang
AU  - Wen F
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Liu, Songlian
AU  - Liu S
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Fang, Fang
AU  - Fang F
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Shen, Erdong
AU  - Shen E
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Zhou, Qiang
AU  - Zhou Q
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Luo, Pan
AU  - Luo P
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Xu, Min
AU  - Xu M
AD  - Department of Hepatobiliary Surgery, Yueyang Central Hospital, Yueyang, China.
FAU - Zhan, Dahe
AU  - Zhan D
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
FAU - Su, Yuqi
AU  - Su Y
AD  - Department of Oncology, Yueyang Central Hospital, Yueyang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230120
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (anlotinib)
RN  - 1548R74NSZ (Tegafur)
SB  - IM
MH  - Humans
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - *Tegafur/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects
MH  - *Pancreatic Neoplasms/pathology
PMC - PMC9897321
OTO - NOTNLM
OT  - GS regimen
OT  - anlotinib
OT  - efficacy
OT  - overall survival
OT  - pancreatic cancer
OT  - progression-free survival
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/02/07 06:00
MHDA- 2023/02/08 06:00
PMCR- 2023/01/01
CRDT- 2023/02/06 03:45
PHST- 2022/11/29 00:00 [received]
PHST- 2023/01/04 00:00 [accepted]
PHST- 2023/02/06 03:45 [entrez]
PHST- 2023/02/07 06:00 [pubmed]
PHST- 2023/02/08 06:00 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1110624 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jan 20;14:1110624. doi: 
      10.3389/fendo.2023.1110624. eCollection 2023.